Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 2, 2010, Pages 351-356

  Vélez, Iván ^a   López, Liliana ^a   Sánchez, Ximena ^b   Mestra, Laureano ^a   Rojas, Carlos ^a   Rodríguez, Erwin ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b DISAN   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE;

ADULT; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LEISHMANIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; PANCREAS DISEASE; PARASITE IDENTIFICATION; RECURRENT DISEASE; SKIN LEISHMANIASIS;

ADULT; ANTIPROTOZOAL AGENTS; CAPSULES; HUMANS; INJECTIONS, INTRAMUSCULAR; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MILITARY PERSONNEL; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE; YOUNG ADULT;

LEISHMANIA BRAZILIENSIS; LEISHMANIA PANAMENSIS;

EID: 77955595281     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.10-0060     Document Type: Article

References (37)

1. Neuber H, 2008. Leishmaniasis. J Dtsch Dermatol Ges 6: 754-765.
2. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev CD004834.
3. Alvar J, Yactayo S, Bern C, 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552-557.
4. Bailey MS, Lockwood DN, 2007. Cutaneous leishmaniasis. Clin Dermatol 25: 203-211.
5. Soto J, Soto P, 2006. Current situation and future of antileishmanial therapy in Colombia. Biomedica (Bogota) 26 (Suppl 1): 194-206.
6. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K, 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599-614.
7. Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366: 1561-1577.
8. Ouellette M, Drummelsmith J, Papadopoulou B, 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7: 257-266.
9. Palumbo E, 2009. Current treatment for cutaneous leishmaniasis: a review. Am J Ther 16: 178-182.
10. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, Pollack H, 2007. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44: 1549-1554.
11. Berman JD, 1996.Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 14: 519-522.
12. Sampaio RN, de Paula CD, Sampaio JH, Furtado Rde S, Leal PP, Rosa TT, Rodrigues ME, Veiga JP, 1997. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop 30: 457-463.
13. Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, Almeida RP, 2004. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190: 1793-1796.
14. Seaton RA, Morrison J, Man I, Watson J, Nathwani D, 1999. Outpatient parenteral antimicrobial therapy - a viable option for the management of cutaneous leishmaniasis. QJM 92: 659-667.
15. Osorio LE, Palacios R, Chica ME, Ochoa MT, 1998. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 351: 498-499.
16. Momeni AZ, Aminjavaheri M, Omidghaemi MR, 2003. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat 14: 26-29.
17. Singh S, Singh R, Sundar S, 1995. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol 34: 120-121.
18. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID, 1998. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg 59: 889-892.
19. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232-236.
20. Bari AU, Rahman SB, 2003. A therapeutic update on cutaneous leishmaniasis. J Coll Physicians Surg Pak 13: 471-476.
21. Croft SL, Engel J, 2006. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100 (Suppl 1): S4-S8.
22. Croft SL, Snowdon D, Yardley V, 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38: 1041-1047.
23. Escobar P, Matu S, Marques C, Croft SL, 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81: 151-157.
24. Nakayama H, Loiseau PM, Bories C, Torres de Ortiz S, Schinini A, Sema E, Rojas de Arias A, Fakhfakh MA, Franck X, Figadere B, Hocquemiller R, Fournet A, 2005. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 49: 4950-4956.
25. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S. Miranda C, Llanos-Cuentas A, Chappuis F, 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272-275.
26. Escobar P, Yardley V, Croft SL, 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45: 1872-1875.
27. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
28. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandai AK, Voss A, Hilgard P, Murray HW, 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352: 1821-1823.
29. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266-1272.
30. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: E57-E61.
31. Velez ID, 1996. Diagnóstico. Antioquia Ud, ed. Leishmaniosis Manual de Procedimientos para el Diagnóstico de la Leishmaniasis Cutánea Americana Medellín Colombia: University of Antioquia, 13-18.
32. Singh S, Dey A, Sivakumar R, 2005. Applications of molecular methods for Leishmania control. Expert Rev Mol Diagn 5: 251-265.
33. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P, 2003. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181. (Pubitemid 36962641)
34. Velez ID, Hendrickx E, Robledo SM, del Pilar Agudelo S, 2001. Gender and cutaneous leishmaniasis in Colombia. Cad Saude Publica 17: 171-180.
35. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210-211.
36. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350-356.
37. Gonzalez LM, Velez ID, 2006. Miltefosine for disseminated cutaneous leishmaniasis. Biomedica (Bogota) 26 (Suppl 1): 13-16.